Cooperative Agreement U34CA297499
Award Date
5/1/25
Completion Date
4/30/28
Dollars Obligated
$248K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Winston-Salem, NC 27157, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $860,545.00 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Miami on July 5, 2024. This project aims to implement and evaluate a Comprehensive Survivorship Care (CSC) intervention across 14 Federally Qualified Health Center (FQHC) primary care clinics in South Florida, which primarily serve racially/ethnically diverse and low-income cancer survivors. The CSC intervention will be...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research (CFDA 93.393) program, will support the development of an Integrative Analysis and Visualization Platform for Cancer Regulatory Genomics. The $416,745 award to the University of Massachusetts Medical School (UMass Medical) aims to create a comprehensive atlas that connects regulatory genomic elements to cancer-associated genes. The project will also perform in-depth...
The National Cancer Institute (NCI) has awarded a $1,853,375 Cooperative Agreement grant under the federal Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Utah. The project, titled "Population Health Management Approaches to Increase Lung Cancer Screening in Community Health Centers", aims to increase the reach and equity of lung cancer screening among underserved populations. The two-phase, sequential multiple assignment randomized trial (SMART) will...
This $720,252 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support a research project led by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The project aims to identify genetic variants that confer risk of common cancers, particularly prostate cancer, across diverse ancestral populations. The key products and services to be delivered include: Profiling regulatory element...
This $946,500 Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) aims to test the effectiveness of strategies to promote high-quality, evidence-based cancer survivorship care in rural primary care practices in Kansas. The project, titled "KANSURVIVE 2.0", will implement a three-arm cluster-randomized, multi-level intervention to provide...
This $998,444 Cooperative Agreement awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program will support implementation and evaluation of a primary care-based cancer survivorship care delivery intervention at 8 community health clinics in Texas. The project aims to enhance the capacity of these clinics to provide high-quality, coordinated cancer survivorship care, particularly for underserved and uninsured populations. The...
This federal Project Grant award of $591,691 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund a pragmatic randomized controlled trial to evaluate an intervention called "Current Together After Cancer" (CTAC) for promoting guideline-concordant colorectal cancer surveillance among stage II and III colorectal cancer survivors. The key objectives are to (1) determine the effect of CTAC on improving survivors' knowledge about and...
This $1,751,176 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) is supporting a research effort by Case Western Reserve University to develop and validate a novel radiomic tumor response (RadTR) classifier for accurately identifying complete response to neoadjuvant therapy in rectal cancer patients. The key products and services being delivered through this 5-year project include: Developing a radiomic-based...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $1,063,155 to Wild Dog Physics LLC to develop and test a novel, comprehensive medical physics quality assurance (QA) device called the RetrieveTM. The project aims to create a prototype that can measure radiation therapy machine performance to within 0.5 mm and 1% relative dose, while also enabling real-time data analysis and compliance...
This $357,939 Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop an in silico (computer simulation) platform to optimize liver transarterial embolization (TAE) for liver cancer treatment. The University of California, Davis (UC Davis) is the prime awardee and will leverage its expertise in computational fluid dynamics modeling and artificial intelligence to create a personalized...